293 related articles for article (PubMed ID: 32237195)
1. Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex.
Soldevila-Barreda JJ; Azmanova M; Pitto-Barry A; Cooper PA; Shnyder SD; Barry NPE
ChemMedChem; 2020 Jun; 15(11):982-987. PubMed ID: 32237195
[TBL] [Abstract][Full Text] [Related]
2. Triazole-Based Half-Sandwich Ruthenium(II) Compounds: From
Lenis-Rojas OA; Cabral R; Carvalho B; Friães S; Roma-Rodrigues C; Fernández JAA; Vila SF; Sanchez L; Gomes CSB; Fernandes AR; Royo B
Inorg Chem; 2021 Jun; 60(11):8011-8026. PubMed ID: 33973771
[TBL] [Abstract][Full Text] [Related]
3. Ru
Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
[TBL] [Abstract][Full Text] [Related]
4. Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes.
Sathiya Kamatchi T; Mohamed Subarkhan MK; Ramesh R; Wang H; Małecki JG
Dalton Trans; 2020 Aug; 49(32):11385-11395. PubMed ID: 32776042
[TBL] [Abstract][Full Text] [Related]
5. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
6. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
7. Anticancer Water-Soluble Organoruthenium Complexes: Synthesis and Preclinical Evaluation.
Azmanova M; Rafols L; Cooper PA; Seaton CC; Shnyder SD; Pitto-Barry A
Chembiochem; 2022 Sep; 23(18):e202200259. PubMed ID: 35838006
[TBL] [Abstract][Full Text] [Related]
8. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
9. Highly Cytotoxic Ruthenium(II)-Arene Complexes from Bulky 1-Pyrenylphosphane Ligands.
Brissos RF; Clavero P; Gallen A; Grabulosa A; Barrios LA; Caballero AB; Korrodi-Gregório L; Pérez-Tomás R; Muller G; Soto-Cerrato V; Gamez P
Inorg Chem; 2018 Dec; 57(23):14786-14797. PubMed ID: 30444630
[TBL] [Abstract][Full Text] [Related]
10. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
11. Half-Sandwich Ru(
Lenis-Rojas OA; Robalo MP; Tomaz AI; Fernandes AR; Roma-Rodrigues C; Teixeira RG; Marques F; Folgueira M; Yáñez J; Gonzalez AA; Salamini-Montemurri M; Pech-Puch D; Vázquez-García D; Torres ML; Fernández A; Fernández JJ
Inorg Chem; 2021 Mar; 60(5):2914-2930. PubMed ID: 33570919
[TBL] [Abstract][Full Text] [Related]
12. Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway.
Chen L; Wang J; Cai X; Chen S; Zhang J; Li B; Chen W; Guo X; Luo H; Chen J
Bioorg Chem; 2022 Feb; 119():105516. PubMed ID: 34856444
[TBL] [Abstract][Full Text] [Related]
13. Novel NHC-coordinated ruthenium(II) arene complexes achieve synergistic efficacy as safe and effective anticancer therapeutics.
Chen C; Xu C; Li T; Lu S; Luo F; Wang H
Eur J Med Chem; 2020 Oct; 203():112605. PubMed ID: 32688202
[TBL] [Abstract][Full Text] [Related]
14. New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action.
Pavlović M; Nikolić S; Gligorijević N; Dojčinović B; Aranđelović S; Grgurić-Šipka S; Radulović S
J Biol Inorg Chem; 2019 Mar; 24(2):297-310. PubMed ID: 30762123
[TBL] [Abstract][Full Text] [Related]
15. A nuclear permeable Ru(ii)-based photoactivated chemotherapeutic agent towards a series of cancer cells: in vitro and in vivo studies.
Tian N; Feng Y; Sun W; Lu J; Lu S; Yao Y; Li C; Wang X; Zhou Q
Dalton Trans; 2019 May; 48(19):6492-6500. PubMed ID: 30994660
[TBL] [Abstract][Full Text] [Related]
16. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
17. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.
Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L
Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659
[TBL] [Abstract][Full Text] [Related]
18. Effect of
Mukherjee A; Acharya S; Purkait K; Chakraborty K; Bhattacharjee A; Mukherjee A
Inorg Chem; 2020 May; 59(9):6581-6594. PubMed ID: 32295347
[TBL] [Abstract][Full Text] [Related]
19. Niacin-ligated platinum(iv)-ruthenium(ii) chimeric complexes synergistically suppress tumor metastasis and growth with potentially reduced toxicity in vivo.
Shu L; Ren L; Wang Y; Fang T; Ye Z; Han W; Chen C; Wang H
Chem Commun (Camb); 2020 Mar; 56(20):3069-3072. PubMed ID: 32049075
[TBL] [Abstract][Full Text] [Related]
20. Anticancer Activity of Electron-Deficient Metal Complexes against Colorectal Cancer in vitro Models.
Azmanova M; Soldevila-Barreda J; Bani Hani H; Lord RM; Pitto-Barry A; Picksley SM; Barry NPE
ChemMedChem; 2019 Nov; 14(22):1887-1893. PubMed ID: 31545555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
